Skip to content

Study · Randomized controlled trial · n = 148 · 2021

3 results

Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial.

Mahlapuu M, Sidorowicz A, Mikosinski J, Krzyżanowski M, Orleanski J, Twardowska-Saucha K, Nykaza A, Dyaczynski M, Belz-Lagoda B, Dziwiszek G, Kujawiak M, Karczewski M and 8 more

Show all authors

Sjöberg F, Grzela T, Wegrzynowski A, Thunarf F, Björk J, Ekblom J, Jawien A, Apelqvist J

Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society23 Oct 2021Cited by 36 (Europe PMC)

PMID34687253 (opens in a new tab)PMCIDPMC9298190 (opens in a new tab)DOI10.1111/wrr.12977 (opens in a new tab)PepBankPUB-34687253
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In 148 patients with hard-to-heal venous leg ulcers on compression therapy, topical LL‑37 (0.5 or 1.6 mg/mL) did not significantly improve healing versus placebo in the full study population.

    In plain wordsIn people with hard-to-heal leg ulcers, LL‑37 applied topically did not improve healing more than placebo overall.

    Peptide
    LL-37
    Outcome
    No significant changeUlcer healing in the full study population
    Study

    n = 148

    Comparator
    Placebo
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    0.5 or 1.6 mg/mL · topicalAs given in this study (human).

    Source sentences

    Summary
    Efficacy analysis performed on the full study population did not identify any significant improvement in healing in patients treated with LL-37 as compared with the placebo.
    1 context sentence
    Summary · context
    This clinical trial HEAL LL-37 was a phase IIb double-blind, randomized, placebo-controlled study, with the aim to evaluate the efficacy and safety of a new drug LL-37 for topical administration, in combination with compression therapy, in 148 patients suffering from hard-to-heal venous leg ulcers.
  2. 02HumanRandomized controlled trialSafety outcome

    In 148 patients with hard-to-heal venous leg ulcers, topical LL‑37 at 0.5 and 1.6 mg/mL was reported as well tolerated and safe.

    In plain wordsIn people with hard-to-heal leg ulcers, topical LL‑37 was reported as well tolerated at both strengths.

    Peptide
    LL-37
    Outcome
    Not applicableSafety and tolerability of topical LL-37
    Study

    n = 148

    Outcome group
    Adverse events · Whole body
    Studied dose
    0.5 or 1.6 mg/mL · topicalAs given in this study (human).

    Source sentences

    Summary
    The study drug was well tolerated and safe in both dose strengths.
    1 context sentence
    Summary · context
    This clinical trial HEAL LL-37 was a phase IIb double-blind, randomized, placebo-controlled study, with the aim to evaluate the efficacy and safety of a new drug LL-37 for topical administration, in combination with compression therapy, in 148 patients suffering from hard-to-heal venous leg ulcers.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In a post hoc subgroup of patients with venous leg ulcers of at least 10 cm2 at randomization, LL‑37 improved several interrelated healing parameters versus placebo.

    In plain wordsIn a post hoc subgroup of people with large leg ulcers, LL‑37 improved several healing measures versus placebo.

    Peptide
    LL-37
    Outcome
    IncreaseHealing parameters in patients with target wounds of at least 10 cm2 (post hoc subgroup)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Wound healing · Skin and wound
    Studied dose
    0.5 or 1.6 mg/mL · topicalAs given in this study (human).

    Source sentences

    Summary
    a post hoc analysis revealed statistically significant improvement with LL-37 treatment in several interrelated healing parameters in the subgroup of patients with large target wounds (a wound area of at least 10 cm2 at randomization)
    1 context sentence
    Summary · context
    This clinical trial HEAL LL-37 was a phase IIb double-blind, randomized, placebo-controlled study, with the aim to evaluate the efficacy and safety of a new drug LL-37 for topical administration, in combination with compression therapy, in 148 patients suffering from hard-to-heal venous leg ulcers.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 12:39 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.